1. A 44-year-old man with opioid use disorder (OUD) is stable on methadone 100 mg/day through an opioid treatment program. He is diagnosed with pulmonary tuberculosis and started on a standard four-drug regimen including rifampin. Two weeks later he reports intense cravings, diaphoresis, and insomnia. His methadone dose has not been changed. Which of the following best explains his symptoms and the mechanism responsible?
A) Rifampin inhibits CYP3A4 (cytochrome P450 3A4)-mediated metabolism of methadone, causing methadone plasma concentrations to rise above therapeutic levels and producing opioid toxicity symptoms including diaphoresis; the correct response is dose reduction
B) Rifampin displaces methadone from alpha-1-acid glycoprotein binding sites, acutely increasing the free methadone fraction and producing paradoxical opioid withdrawal through rapid receptor desensitization; protein binding displacement resolves within 72 hours without dose adjustment
C) Rifampin inhibits P-glycoprotein (P-gp) efflux at the blood-brain barrier, reducing central nervous system penetration of methadone and producing functional withdrawal symptoms despite normal plasma methadone concentrations; the correct response is switching to an opioid not affected by P-gp
D) Rifampin is a potent inducer of CYP3A4, the primary hepatic enzyme responsible for methadone metabolism; CYP3A4 induction dramatically accelerates methadone clearance, reducing plasma methadone concentrations below the threshold required to suppress opioid withdrawal — a pharmacokinetic interaction that typically manifests within 1–2 weeks of rifampin initiation and requires substantial methadone dose increases, sometimes 50% or more above baseline, to restore adequate plasma concentrations
E) Rifampin directly activates mu-opioid receptors (MOR) in the locus coeruleus through a non-opioid mechanism, competing with methadone for receptor occupancy and precipitating withdrawal by reducing net MOR activation below the threshold required for opioid suppression
ANSWER: D
Rationale:
This question asked you to integrate knowledge of CYP3A4 induction pharmacokinetics with the clinical consequences of methadone-rifampin co-administration. Option D is correct. Rifampin (rifampicin) is one of the most potent CYP3A4 inducers in clinical use, acting through activation of the pregnane X receptor (PXR) to dramatically upregulate CYP3A4 expression in the liver and intestinal wall. Methadone is primarily metabolized by CYP3A4 (and to a lesser extent CYP2D6 and CYP2B6) to its inactive metabolite EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine). CYP3A4 induction by rifampin increases methadone clearance severalfold, reducing plasma methadone concentrations below the steady-state level that had previously suppressed opioid withdrawal symptoms. The interaction typically becomes clinically apparent within 1–2 weeks of rifampin initiation, corresponding to the time required for CYP3A4 upregulation to reach maximal effect. Patients on stable methadone maintenance doses may require increases of 50% or more to restore adequate plasma concentrations during rifampin therapy. This interaction is well established and represents one of the most clinically significant drug-drug interactions in opioid use disorder treatment.
Option A: Option A is incorrect because rifampin is a CYP3A4 inducer, not an inhibitor; CYP3A4 inhibition would raise methadone concentrations and produce toxicity, not withdrawal.
Option B: Option B is incorrect because rifampin does not produce clinically significant protein binding displacement of methadone; protein binding displacement interactions are rarely clinically meaningful, and this mechanism does not produce the described pattern of withdrawal onset two weeks after initiation.
Option C: Option C is incorrect because while P-glycoprotein interactions can affect CNS drug penetration, rifampin's interaction with methadone is primarily a CYP3A4 induction effect on systemic plasma concentrations, not a P-gp effect at the blood-brain barrier; additionally, rifampin induces rather than inhibits P-gp.
Option E: Option E is incorrect because rifampin has no direct MOR agonist or antagonist activity; it does not compete with methadone at opioid receptors through any mechanism.
2. A 71-year-old woman with postherpetic neuralgia (PHN) has had an inadequate response to gabapentin at maximally tolerated doses and nortriptyline at therapeutic plasma concentrations. Her pain remains at 6/10 with significant allodynia. Her clinician is considering adding an opioid. Which of the following reasoning chains correctly identifies the most appropriate next opioid agent and its pharmacological rationale in this clinical context?
A) Tramadol is the most appropriate next agent because its dual mechanism — mu-opioid receptor (MOR) agonism combined with serotonin and norepinephrine reuptake inhibition — provides mechanistic complementarity with the failed first-line agents; its norepinephrine reuptake inhibition augments descending noradrenergic inhibition through the same pathway targeted by nortriptyline, and its MOR component adds opioid-mediated modulation of spinal nociceptive transmission; tramadol occupies a lower risk tier than strong opioids in neuropathic pain guidelines, making it the appropriate intermediate step before escalating to full MOR agonists
B) Extended-release morphine is the most appropriate next agent because strong full MOR agonists have higher number-needed-to-treat (NNT) values than tramadol in PHN and therefore produce superior pain relief; morphine's lack of monoaminergic activity avoids pharmacodynamic overlap with the failed nortriptyline, making it mechanistically complementary
C) Methadone is the most appropriate next agent because it is the only opioid with NMDA receptor antagonist activity, and central sensitization is the dominant mechanism in PHN after gabapentinoid failure; its NMDA antagonism directly targets the wind-up and long-term potentiation changes that gabapentin failed to suppress
D) Buprenorphine transdermal patch is the most appropriate next agent because its kappa-opioid receptor (KOR) antagonism specifically reverses the dysphoric component of PHN that nortriptyline failed to address, and its ceiling effect for respiratory depression makes it safer than tramadol in a 71-year-old patient with presumed age-related respiratory reserve reduction
E) No opioid is appropriate at this stage because PHN guidelines require failure of at least four first-line agents before any opioid can be considered; the patient has failed only two first-line agents and should next receive the 5% lidocaine patch and the 8% capsaicin patch sequentially before any opioid is introduced
ANSWER: A
Rationale:
This question asked you to integrate the pharmacological mechanisms of available opioid options with the clinical context of PHN failing two first-line agents. Option A is correct. When two first-line neuropathic pain agents have failed, guidelines from the IASP NeuPSIG position strong opioids as third-line therapy, but tramadol occupies an intermediate position — lower risk than strong full MOR agonists — and may be considered at this stage of the treatment sequence. The pharmacological rationale for tramadol in this patient is mechanistic complementarity: gabapentin targeted voltage-gated calcium channel alpha-2-delta subunits to reduce presynaptic neurotransmitter release, and nortriptyline combined sodium channel blockade with norepinephrine reuptake inhibition to augment descending inhibition. Tramadol's norepinephrine reuptake inhibition component reinforces the same descending noradrenergic pathway that nortriptyline targeted (which produced partial but insufficient benefit), while its MOR agonist activity adds a distinct spinal and supraspinal opioid-mediated analgesic mechanism not covered by the prior agents. This mechanistic layering, combined with tramadol's lower long-term risk profile compared to strong opioids, makes it the appropriate intermediate step.
Option B: Option B is incorrect because strong full MOR agonists such as morphine do not have higher NNT values than tramadol in PHN — the NNT values are broadly comparable — and the reasoning that morphine's lack of monoaminergic activity makes it mechanistically complementary does not constitute a reason to skip the intermediate tramadol step in a guideline-structured treatment sequence.
Option C: Option C is incorrect because while methadone's NMDA antagonism is a legitimate mechanistic rationale in PHN, methadone is not the appropriate next agent after two first-line failures in an elderly patient; its complex pharmacokinetics, QTc prolongation risk, drug interaction burden, and requirement for specialist prescriber familiarity make it a later-line option, not the next agent after gabapentin and nortriptyline.
Option D: Option D is incorrect because buprenorphine's primary rationale in neuropathic pain is KOR antagonism and renal safety, not reversal of a dysphoric component specifically attributable to nortriptyline failure; the clinical reasoning in Option D does not reflect established guideline positioning of buprenorphine in PHN.
Option E: Option E is incorrect because guidelines do not require failure of four first-line agents before any opioid; the IASP NeuPSIG framework positions opioids as third-line after failure of first-line and second-line agents, and two first-line failures with continued significant pain is a clinically appropriate point to consider advancing in the treatment sequence.
3. A 67-year-old man with alcoholic cirrhosis (Child-Pugh Class B) and diabetic nephropathy (eGFR 24 mL/min/1.73m²) requires ongoing opioid analgesia for cancer-related pain. Applying both the renal and hepatic constraints simultaneously, which opioid selection and dosing principle best integrates these two pharmacokinetic limitations?
A) Morphine is the preferred agent because its glucuronide metabolites are renally cleared, removing the burden of hepatic metabolism in a patient with impaired liver function; the renal impairment is managed by reducing the morphine dose by 25%, which is sufficient to prevent M3G and M6G accumulation at eGFR 24 mL/min/1.73m²
B) Methadone is preferred because its primary fecal excretion pathway bypasses both impaired renal metabolite clearance and impaired hepatic glucuronidation; standard methadone doses require no adjustment in combined renal and hepatic impairment because neither elimination pathway is meaningfully affected
C) Hydromorphone is the preferred agent in combined organ impairment because its H3G metabolite is analgesically active and accumulates in renal failure, providing prolonged analgesia that compensates for reduced hepatic production of the parent drug in cirrhosis; no dose adjustment is required
D) Oxycodone is preferred in this patient because it undergoes exclusively renal excretion as unchanged parent compound, bypassing hepatic metabolism entirely and avoiding both the hepatic impairment concern and the metabolite accumulation risk of morphine and hydromorphone
E) Fentanyl is the most appropriate agent because CYP3A4-mediated hepatic metabolism to inactive norfentanyl produces no renally cleared toxic metabolites — addressing the renal constraint — while the hepatic impairment requires dose reduction and extended dosing intervals to account for reduced CYP3A4 activity and increased oral bioavailability from reduced first-pass extraction; both constraints are managed within a single agent by careful dose titration
ANSWER: E
Rationale:
This question asked you to apply renal and hepatic pharmacokinetic constraints simultaneously to select the safest opioid in a patient with both impairments. Option E is correct. Fentanyl satisfies both constraints through its metabolic profile: its primary hepatic CYP3A4 (cytochrome P450 3A4)-mediated conversion to norfentanyl produces an inactive metabolite that is not renally cleared in clinically significant quantities, directly addressing the eGFR 24 mL/min/1.73m² constraint that makes morphine, hydromorphone, and codeine dangerous. The hepatic impairment (Child-Pugh Class B) requires fentanyl dose adjustment because: reduced CYP3A4 activity slows fentanyl's metabolic clearance and prolongs its effective half-life; reduced first-pass extraction increases the oral bioavailability of any oral fentanyl formulation; and reduced alpha-1-acid glycoprotein synthesis increases the free fentanyl fraction. These hepatic effects are managed by dose reduction, extended dosing intervals, and careful clinical monitoring — adjustments that are feasible within the drug's pharmacokinetic framework. Buprenorphine would be an equally valid choice for the same fundamental reason (no accumulating renally toxic metabolites; dose reduction in hepatic impairment).
Option A: Option A is incorrect because morphine is contraindicated in eGFR 24 mL/min/1.73m² regardless of hepatic status; M3G and M6G accumulate dangerously at this level of renal function, and a 25% dose reduction does not prevent toxic metabolite accumulation in significant renal impairment.
Option B: Option B is incorrect because methadone's fecal excretion does not make it safe in combined organ impairment without adjustment; Child-Pugh Class B hepatic impairment reduces CYP3A4 activity, slowing methadone metabolism and causing accumulation, and methadone's complex pharmacokinetics, QTc prolongation risk, and drug interaction burden require specialist management that makes it unsuitable as a default agent in this setting.
Option C: Option C is incorrect and contains a clinically dangerous error: H3G (hydromorphone-3-glucuronide) is neuroexcitatory and pro-nociceptive, not analgesically active; it accumulates in renal failure and causes myoclonus and cognitive toxicity, not prolonged analgesia. Hydromorphone is contraindicated in eGFR below 30 mL/min/1.73m².
Option D: Option D is incorrect because oxycodone does not undergo exclusively renal excretion as unchanged parent compound; it is primarily hepatically metabolized by CYP3A4 and CYP2D6 to active metabolites including oxymorphone, and these metabolites accumulate in renal impairment.
4. A 78-year-old woman with chronic cancer pain has been stable on oral morphine 30 mg every 4 hours for six months. Over the past three weeks she has developed worsening pain despite no change in her dose, along with new-onset myoclonic jerks and cognitive impairment. Her serum creatinine has risen from 0.8 to 2.1 mg/dL over the same period. Which of the following best explains the complete clinical picture and the mechanism responsible?
A) The worsening pain and myoclonus represent opioid tolerance and opioid-induced hyperalgesia (OIH) respectively; both are caused by progressive mu-opioid receptor (MOR) downregulation from chronic morphine exposure, and the rising creatinine is an unrelated finding from contrast nephropathy during a recent imaging study
B) The rising creatinine reflects declining renal function that has reduced clearance of morphine-3-glucuronide (M3G), a neuroexcitatory and pro-nociceptive metabolite; accumulating M3G opposes morphine's analgesic effect (explaining worsening pain despite stable dose) and produces the myoclonus and cognitive impairment through neuroexcitatory mechanisms at glycine and GABA-A receptors; the correct response is to discontinue morphine and transition to a renally safe opioid such as fentanyl
C) The worsening pain reflects progressive disease rather than a pharmacological mechanism; the myoclonus is a paraneoplastic neurological complication unrelated to morphine; rising creatinine indicates renal metastases; the morphine dose should be increased to address the disease progression
D) The accumulation of morphine-6-glucuronide (M6G) from declining renal clearance produces the myoclonus and cognitive impairment through excessive MOR activation in the cortex and spinal cord; paradoxically, M6G accumulation also causes worsening pain by competitively displacing morphine from spinal MOR, reducing net analgesia at the dose-limiting level of cortical toxicity
E) Declining renal function reduces hepatic glucuronidation of morphine through the hepatorenal axis, causing parent morphine to accumulate rather than its metabolites; the elevated parent morphine concentration causes paradoxical pain sensitization through sigma receptor activation and myoclonus through cerebellar MOR overstimulation
ANSWER: B
Rationale:
This question asked you to integrate declining renal function, morphine metabolite pharmacology, and a clinical presentation of worsening pain with neurotoxicity. Option B is correct. The clinical picture — worsening pain despite stable morphine dose, new myoclonus, and cognitive impairment coinciding with a doubling of serum creatinine — is the classic presentation of morphine-3-glucuronide (M3G) accumulation from declining renal function. M3G is the predominant glucuronide metabolite of morphine (constituting approximately 55–75% of the glucuronide fraction) and is pharmacologically paradoxical: it is neuroexcitatory and pro-nociceptive, acting at glycine and GABA-A receptors to produce excitation rather than inhibition. As renal clearance falls, M3G accumulates and opposes morphine's analgesic effect at the spinal level, producing worsening pain despite unchanged opioid dose — a presentation that can mislead clinicians into escalating the morphine dose, which worsens M3G accumulation further. The myoclonus and cognitive impairment are direct neuroexcitatory consequences of M3G at supraspinal and spinal levels. The correct response is discontinuation of morphine and transition to a renally safe opioid — fentanyl (inactive norfentanyl metabolite) or buprenorphine — with careful monitoring during the transition.
Option A: Option A is incorrect because while opioid tolerance and OIH are real phenomena, the temporal correlation of the clinical deterioration with rising creatinine and the specific triad of worsening pain, myoclonus, and cognitive impairment is characteristic of M3G accumulation, not tolerance or OIH; the creatinine rise is not incidental.
Option C: Option C is incorrect because attributing the complete triad to disease progression and paraneoplastic syndrome without investigating the pharmacokinetic explanation is clinically dangerous; the temporal correlation with creatinine rise strongly implicates morphine metabolite accumulation, and dismissing the pharmacological mechanism risks continued toxicity.
Option D: Option D is incorrect because M6G does not cause myoclonus or cognitive impairment through cortical MOR activation — M6G is a potent MOR agonist and its accumulation produces prolonged opioid toxicity (sedation, respiratory depression), not the neuroexcitatory picture described; and M6G does not competitively displace morphine from spinal MOR to reduce analgesia.
Option E: Option E is incorrect because declining renal function does not impair hepatic glucuronidation through a hepatorenal axis mechanism; the hepatic metabolism of morphine is not meaningfully impaired by renal failure, and parent morphine does not have sigma receptor-mediated pain sensitization as a primary mechanism.
5. A neurologist is comparing the expected opioid analgesic response in two patients: one with postherpetic neuralgia (PHN) affecting the right thoracic dermatome, and one with central post-stroke pain (CPSP) following a left thalamic infarct producing right-sided burning pain and allodynia. Which of the following correctly explains why opioid responsiveness is generally more variable and less predictable in the CPSP patient than in the PHN patient?
A) Opioids are less effective in CPSP because the thalamic infarct destroys mu-opioid receptor (MOR)-expressing neurons in the pain-processing thalamus, physically eliminating the primary supraspinal site of opioid analgesia; PHN preserves thalamic MOR because the pathology is confined to the peripheral nerve and dorsal root ganglion
B) Opioids are less effective in CPSP because stroke-associated neuroinflammation upregulates kappa-opioid receptors (KOR) in the affected thalamus, and KOR activation paradoxically reduces analgesic efficacy of MOR agonists through cross-receptor inhibitory signaling at the cellular level
C) In PHN, the primary pathological changes — ectopic discharge from injured primary afferents and central sensitization in the dorsal horn — occur at levels of the pain-processing system that mu-opioid receptors (MOR) effectively modulate; in CPSP, the injury affects spinothalamic tract pathways, thalamic nuclei, or cortical pain-processing areas above the level of opioid-sensitive spinal circuits, and pain is maintained by pathological reorganization in supraspinal networks that MOR agonism does not reliably normalize
D) Opioids are less effective in CPSP because thalamic injury eliminates descending noradrenergic and serotonergic pain inhibitory pathways that originate in the thalamus; without this descending inhibition, opioids cannot access the spinal dorsal horn circuits they normally modulate through these descending pathways
E) Opioid responsiveness is identical between PHN and CPSP at equivalent pain intensities; the clinical impression of reduced opioid efficacy in CPSP reflects prescriber reluctance to titrate to adequate doses in stroke patients rather than a pharmacological difference in opioid receptor engagement between peripheral and central neuropathic pain
ANSWER: C
Rationale:
This question asked you to explain the mechanistic basis for reduced and more variable opioid responsiveness in central compared to peripheral neuropathic pain. Option C is correct. The opioid analgesic system primarily modulates nociceptive transmission at the spinal dorsal horn — through presynaptic inhibition of primary afferent neurotransmitter release and postsynaptic hyperpolarization of dorsal horn projection neurons — and at supraspinal sites including the periaqueductal gray (PAG) and rostral ventromedial medulla (RVM). In PHN, the pathological changes that drive pain — ectopic discharge from Nav channel-upregulated primary afferents and NMDA receptor-mediated central sensitization in the dorsal horn — occur at levels of the pain processing system that are within or immediately upstream of these opioid-sensitive circuits. MOR agonism can therefore modulate the nociceptive signal at pharmacologically relevant points in the pathway. In CPSP, the causative injury is at the level of the spinothalamic tract, thalamic relay nuclei, or cortical pain-processing areas — above the primary locus of spinal opioid action. Pain in CPSP is maintained by pathological reorganization and dysrhythmic activity in supraspinal networks (thalamocortical circuits) that MOR agonism does not reliably normalize, explaining the more variable and incomplete opioid response.
Option A: Option A is incorrect because the mechanism is not physical destruction of thalamic MOR neurons; thalamic injury in CPSP does not eliminate MOR, and the reduced opioid efficacy reflects circuit-level reorganization above opioid-sensitive spinal circuits rather than receptor loss.
Option B: Option B is incorrect because KOR upregulation producing cross-receptor inhibition of MOR analgesia is not an established mechanism of opioid resistance in CPSP; this pharmacological interaction does not occur through the signaling cascade described.
Option D: Option D is incorrect because the descending noradrenergic and serotonergic inhibitory pathways originate in the brainstem (locus coeruleus and raphe nuclei), not in the thalamus; thalamic injury in CPSP does not disrupt these descending inhibitory systems.
Option E: Option E is incorrect because the reduced and variable opioid responsiveness in CPSP is a pharmacologically established phenomenon documented in controlled studies — not a prescriber behavior artifact; the mechanistic explanation is the location of the causative injury relative to opioid-sensitive pain circuits.
6. A 52-year-old man with opioid use disorder (OUD) is stable on buprenorphine-naloxone 16 mg/day sublingually. He is diagnosed with pancreatic cancer and develops severe pain rated 9/10 that is inadequately controlled. His oncologist prescribes oxycodone 10 mg every 4 hours, but the patient reports no analgesic effect. Which of the following correctly explains this failure and identifies the appropriate management principle?
A) Oxycodone is ineffective because buprenorphine inhibits CYP2D6-mediated conversion of oxycodone to its active metabolite oxymorphone; the correct management is to switch oxycodone to a non-CYP2D6-dependent opioid such as morphine, which does not require metabolic activation
B) Oxycodone is ineffective because buprenorphine-induced upregulation of mu-opioid receptor (MOR) internalization has reduced the total MOR density available for activation; the correct management is to increase the oxycodone dose until receptor saturation is achieved above the internalization threshold
C) Oxycodone is ineffective because the naloxone component of buprenorphine-naloxone, when absorbed sublingually, reaches sufficient systemic concentrations to competitively antagonize oxycodone at spinal MOR; the correct management is to transition the patient from buprenorphine-naloxone to buprenorphine monoproduct, after which oxycodone will be effective
D) Buprenorphine has exceptionally high MOR affinity and slow receptor dissociation kinetics, occupying the majority of available MOR at therapeutic doses; full MOR agonists such as oxycodone cannot effectively compete for receptor occupancy, explaining the analgesic failure; management options include substantially increasing the buprenorphine dose to exploit its partial agonist analgesic ceiling for cancer pain, or transitioning the patient to a full MOR agonist with careful planning given the high-affinity receptor competition during the transition period
E) Oxycodone is ineffective because buprenorphine's kappa-opioid receptor (KOR) antagonism blocks the KOR-mediated component of oxycodone's analgesia; since cancer pain has a large KOR-mediated component, the correct management is to add a selective KOR agonist alongside continued buprenorphine and oxycodone
ANSWER: D
Rationale:
This question asked you to apply buprenorphine's receptor pharmacology to explain a clinical failure of full MOR agonist analgesia in a patient maintained on buprenorphine. Option D is correct. Buprenorphine has an exceptionally high affinity for the MOR — higher than any other clinically used opioid — and its receptor dissociation kinetics are slow (it unbinds slowly from MOR once bound). At therapeutic maintenance doses of 16 mg/day, buprenorphine occupies the vast majority of available MOR. When a full MOR agonist such as oxycodone is added, it cannot effectively compete with buprenorphine for receptor occupancy because buprenorphine's binding affinity far exceeds oxycodone's; the result is that oxycodone produces little or no net increase in MOR activation beyond what buprenorphine already provides — explaining the complete analgesic failure. Management options for this clinically important scenario include: increasing the buprenorphine dose itself (buprenorphine maintains analgesic activity through its partial MOR agonism, and higher doses may provide additional analgesia even with a partial agonist ceiling, though this ceiling limits efficacy in severe cancer pain); or transitioning the patient from buprenorphine to a full MOR agonist, which requires careful planning because the high MOR affinity of residual buprenorphine will initially block the full agonist's effect, and adequate analgesia during the transition period can be challenging to achieve.
Option A: Option A is incorrect because buprenorphine does not inhibit CYP2D6; the analgesic failure is a pharmacodynamic receptor competition phenomenon, not a pharmacokinetic metabolic interaction. Morphine does not require CYP2D6 for its primary analgesic activity.
Option B: Option B is incorrect because buprenorphine-induced MOR internalization is not the established mechanism of full agonist blockade; the mechanism is competitive receptor occupancy through high binding affinity, not receptor density reduction through internalization.
Option C: Option C is incorrect because naloxone in sublingual buprenorphine-naloxone formulations has very poor sublingual bioavailability — this is by design, as the naloxone component is intended to deter intravenous misuse, not to provide systemic opioid antagonism during therapeutic sublingual use; systemic naloxone concentrations after sublingual buprenorphine-naloxone are negligible and do not antagonize concurrently administered opioids.
Option E: Option E is incorrect because oxycodone does not have clinically meaningful KOR agonist activity at therapeutic doses, and cancer pain analgesia does not depend on a large KOR-mediated component; the analgesic failure is explained entirely by buprenorphine's high MOR affinity blocking oxycodone's MOR activity.
7. A 61-year-old man with end-stage renal disease (ESRD) on hemodialysis is receiving morphine 60 mg oral every 4 hours for cancer pain but has developed myoclonus and worsening cognitive impairment consistent with morphine metabolite toxicity. His pain control has been adequate. His team decides to rotate him to transdermal fentanyl. Which of the following correctly applies both the rationale for the agent switch and the dose calculation principle governing opioid rotation?
A) The switch to fentanyl is pharmacokinetically justified because fentanyl's CYP3A4 (cytochrome P450 3A4)-mediated metabolism to inactive norfentanyl produces no renally cleared toxic metabolites, directly eliminating the source of M3G and M6G accumulation; the equianalgesic fentanyl dose calculated from the total daily morphine dose must then be reduced by approximately 25–50% below the calculated equianalgesic dose to account for incomplete cross-tolerance between morphine and fentanyl — yielding a starting fentanyl dose that is conservative relative to equianalgesic equivalence
B) The switch to fentanyl is appropriate because fentanyl undergoes exclusive renal excretion as unchanged parent compound, bypassing hepatic metabolism entirely; the equianalgesic fentanyl dose should match the calculated morphine equivalent exactly, with no reduction, because the dose reduction principle applies only when rotating between two drugs of the same chemical class
C) The switch to fentanyl is appropriate because fentanyl's low molecular weight allows it to be cleared by hemodialysis, preventing any accumulation of parent drug or metabolites during dialysis sessions; the equianalgesic dose should be increased by 20% above calculated equivalence to compensate for dialysis-related fentanyl clearance between sessions
D) The switch to fentanyl eliminates the M3G and M6G toxicity because fentanyl competitively displaces accumulated M3G and M6G from their neuroexcitatory receptor binding sites, pharmacodynamically reversing the toxicity while providing analgesia; the equianalgesic dose requires no adjustment because fentanyl's receptor competition effect replaces the toxic metabolite effect
E) The switch to fentanyl is appropriate for the metabolite toxicity reason stated, but incomplete cross-tolerance does not apply when rotating away from a drug causing active toxicity; the full equianalgesic fentanyl dose should be used without reduction because the patient's pain control was adequate on morphine and any dose reduction risks undertreating the pain
ANSWER: A
Rationale:
This question asked you to integrate two simultaneous principles: the pharmacokinetic rationale for choosing fentanyl in ESRD, and the dose calculation principle governing opioid rotation. Option A is correct on both counts. The switch from morphine to fentanyl is pharmacokinetically justified by fentanyl's metabolic profile: CYP3A4-mediated hepatic conversion to norfentanyl produces an inactive metabolite without meaningful renal clearance, directly eliminating the source of the neuroexcitatory M3G and analgesic-but-accumulating M6G that are causing the patient's toxicity. The second principle — incomplete cross-tolerance — applies to all opioid rotations regardless of the reason for switching. Incomplete cross-tolerance exists because chronic exposure to one opioid produces tolerance that is receptor-specific and not fully transferable to a different opioid with a slightly different receptor binding profile and activation pattern. When rotating, the calculated equianalgesic dose of the new opioid will therefore overestimate the clinically effective dose needed to achieve equivalent analgesia; using the full equianalgesic dose risks toxicity from relative overdose of the new agent. The standard approach is to reduce the calculated equianalgesic fentanyl dose by 25–50% and titrate upward as needed, while monitoring closely.
Option B: Option B is incorrect because fentanyl does not undergo exclusive renal excretion as unchanged compound — it undergoes hepatic CYP3A4 metabolism — and the incomplete cross-tolerance dose reduction principle applies universally in opioid rotation, not selectively within chemical classes.
Option C: Option C is incorrect because fentanyl is highly lipophilic and extensively protein-bound, and is not meaningfully cleared by hemodialysis; the premise of dialysis clearance of fentanyl is pharmacokinetically false.
Option D: Option D is incorrect because fentanyl does not pharmacodynamically displace M3G or M6G from receptor binding sites — M3G acts at glycine and GABA-A receptors, not MOR, and fentanyl does not reverse M3G toxicity by receptor competition; fentanyl eliminates future metabolite production by replacing morphine, but does not reverse accumulated M3G effects through displacement.
Option E: Option E is incorrect because incomplete cross-tolerance applies universally in opioid rotation — including when the rotation is driven by toxicity rather than inadequate analgesia; the prior adequacy of pain control on morphine means the patient has achieved tolerance to morphine's effects, making the full equianalgesic fentanyl dose an overestimate of what is needed at the new receptor, not a validated safe starting dose.
8. A 58-year-old woman with painful diabetic peripheral neuropathy (DPN) and comorbid major depressive disorder is maintained on sertraline 100 mg/day. She has failed gabapentin and duloxetine (discontinued due to adverse effects). Her clinician is considering either tramadol or tapentadol as the next analgesic agent. Which of the following correctly identifies the pharmacodynamic interaction concern and explains why tapentadol carries a lower risk than tramadol in this specific patient?
A) Tramadol carries higher serotonin syndrome risk than tapentadol in this patient because tramadol requires CYP2D6-mediated activation to its O-desmethyl metabolite (M1), and sertraline's CYP2D6 inhibition prevents this activation — paradoxically increasing the parent tramadol concentration, which has stronger serotonin reuptake inhibition than M1; tapentadol avoids this because it does not require CYP2D6 activation
B) Tramadol and tapentadol carry identical serotonin syndrome risk in this patient because both inhibit serotonin reuptake to the same degree; the correct approach is to avoid both agents and use oxycodone, which has no serotonergic activity, as the next step after gabapentinoid and SNRI failure in DPN
C) Tramadol carries higher serotonin syndrome risk because sertraline inhibits CYP3A4, the enzyme responsible for tramadol's primary metabolism, causing tramadol accumulation and proportionally increased serotonin reuptake inhibition; tapentadol is unaffected because it is metabolized exclusively by glucuronidation, which is not inhibited by sertraline
D) Both tramadol and tapentadol are absolutely contraindicated in patients on any serotonergic antidepressant, including SSRIs; the correct management is to discontinue sertraline, allow a two-week washout, and then initiate either tramadol or tapentadol depending on analgesic requirements
E) Tapentadol carries a lower serotonin syndrome risk than tramadol in this patient because tapentadol's monoaminergic mechanism is predominantly norepinephrine reuptake inhibition with relatively minor serotonin reuptake inhibition, whereas tramadol inhibits both serotonin and norepinephrine reuptake more equally; the reduced serotonergic load of tapentadol combined with sertraline's serotonin transporter blockade is less likely to produce the critical synaptic serotonin excess required for serotonin syndrome than the more pronounced serotonin reuptake inhibition of tramadol combined with sertraline
ANSWER: E
Rationale:
This question asked you to apply the differential serotonergic pharmacology of tramadol and tapentadol to a patient on an SSRI, integrating drug interaction risk with analgesic selection in DPN. Option E is correct. Both tramadol and tapentadol combine MOR agonism with monoamine reuptake inhibition, but their relative selectivity for serotonin versus norepinephrine reuptake differs meaningfully. Tramadol inhibits both serotonin and norepinephrine reuptake with relatively comparable potency at the serotonin transporter (SERT) and norepinephrine transporter (NET). Tapentadol has relatively greater NET inhibition compared to SERT inhibition — its noradrenergic selectivity is substantially higher than its serotonergic activity. When combined with sertraline, a potent SERT inhibitor, the risk of producing sufficient synaptic serotonin excess to trigger serotonin syndrome is higher with tramadol (which adds meaningful SERT blockade on top of sertraline's existing SERT blockade) than with tapentadol (whose SERT contribution is substantially less). Neither agent is absolutely safe in combination with SSRIs, and clinical monitoring for serotonin syndrome features (clonus, hyperreflexia, hyperthermia, agitation) remains necessary, but the risk differential is pharmacologically meaningful. option but the characterization that both agents are equally risky is pharmacologically inaccurate.
Option A: Option A is incorrect in its mechanism: sertraline does inhibit CYP2D6, which does reduce tramadol's CYP2D6-mediated conversion to M1 (reducing opioid analgesia rather than increasing it), but the serotonin syndrome risk with tramadol-sertraline is driven by tramadol's own SERT inhibition combining with sertraline's SERT blockade — not by accumulation of parent tramadol with stronger SERT activity.
Option B: Option B is incorrect because tramadol and tapentadol do not carry identical serotonin syndrome risk; their differential SERT selectivity produces a meaningful risk difference as described in Option E. Oxycodone is a reasonable analgesic
Option C: Option C is incorrect because sertraline does not significantly inhibit CYP3A4 — it is primarily a CYP2D6 inhibitor and a moderate CYP2C19 inhibitor; tramadol's primary metabolism involves CYP2D6 (for M1 formation) and CYP3A4 (for N-desmethyltramadol), and the serotonin syndrome mechanism is SERT-based, not CYP accumulation-based.
Option D: Option D is incorrect because tramadol and tapentadol are not absolutely contraindicated with all SSRIs; the combination requires caution and monitoring, not mandatory SSRI discontinuation, and a two-week washout of sertraline (a non-MAOI SSRI) before opioid initiation is not a clinical standard.
9. A patient with refractory neuropathic pain from chemotherapy-induced peripheral neuropathy (CIPN) is on stable opioid therapy but continues to report severe pain with prominent temporal summation — each successive stimulus produces progressively greater pain intensity. His pain specialist adds low-dose ketamine infusions to his regimen. Which of the following correctly identifies the mechanistic rationale for this combination and explains why ketamine addresses a component of his pain that opioids do not?
A) Ketamine potentiates opioid analgesia by inhibiting mu-opioid receptor (MOR) internalization — the process by which MOR is removed from the cell surface after agonist binding — thereby increasing the number of available MOR available for activation by the concurrent opioid and amplifying its analgesic effect without adding any independent analgesic mechanism
B) Ketamine is an N-methyl-D-aspartate (NMDA) receptor antagonist that blocks the voltage-dependent magnesium channel within the NMDA receptor, preventing the calcium influx that drives central sensitization and wind-up in dorsal horn neurons; because opioids act through MOR to modulate nociceptive transmission but do not directly block NMDA receptor-mediated synaptic amplification, ketamine and opioids target distinct and complementary mechanisms — with opioids reducing the incoming nociceptive signal and ketamine preventing the pathological amplification of that signal at the dorsal horn synapse
C) Ketamine produces analgesia exclusively through sigma receptor activation in the limbic system, reducing the affective and emotional component of pain perception without affecting the sensory-discriminative component targeted by opioids; the combination provides complete pain coverage by addressing both dimensions simultaneously through separate receptor systems
D) Ketamine reverses opioid-induced tolerance by competitively displacing the opioid from MOR at dorsal horn synapses, allowing the receptor to reset to its pre-tolerance sensitivity state; the analgesic benefit of ketamine in opioid-treated patients is therefore entirely attributable to tolerance reversal rather than any independent analgesic mechanism
E) Ketamine acts as a partial MOR agonist with higher receptor affinity than most full agonists, displacing the concurrent opioid from a proportion of MOR and providing analgesia through a receptor activation profile that is less susceptible to tolerance development than full agonism; the combination is effective because ketamine's partial agonism and the full agonist's complete receptor activation produce a synergistic effect at MOR
ANSWER: B
Rationale:
This question asked you to apply NMDA receptor pharmacology to explain the mechanistic rationale for ketamine addition in a patient with opioid-refractory neuropathic pain characterized by temporal summation. Option B is correct. The patient's prominent temporal summation — progressively increasing pain with repeated stimulation — is the clinical signature of wind-up, which is driven by NMDA receptor activation in dorsal horn neurons. As established in the wind-up mechanism: repeated nociceptive stimulation causes cumulative depolarization that relieves the voltage-dependent magnesium block from the NMDA receptor channel, allowing calcium influx that amplifies synaptic transmission progressively with each successive stimulus. Opioids act through MOR at presynaptic and postsynaptic sites to reduce the magnitude of nociceptive transmission but do not directly block the NMDA receptor channel — they reduce the signal entering the amplification circuit but cannot prevent the pathological amplification itself once central sensitization is established. Ketamine, as an NMDA receptor open-channel blocker, enters the activated NMDA receptor channel and blocks it, directly interrupting the calcium influx that drives central sensitization and wind-up. The combination therefore targets two mechanistically distinct and complementary processes: MOR agonism reducing the incoming nociceptive signal, and NMDA antagonism preventing its pathological amplification at the dorsal horn synapse.
Option A: Option A is incorrect because ketamine does not inhibit MOR internalization; this is not an established mechanism of ketamine action, and ketamine's analgesic benefit in opioid-refractory pain is not attributable to receptor surface density changes.
Option C: Option C is incorrect because ketamine's primary analgesic mechanism is NMDA receptor antagonism, not sigma receptor activation; while ketamine does interact with sigma receptors, the analgesic and anti-sensitization effects relevant to neuropathic pain are mediated through NMDA receptor blockade.
Option D: Option D is incorrect because ketamine does not competitively displace opioids from MOR; ketamine has no clinically meaningful MOR affinity, and while NMDA receptor antagonism can attenuate opioid tolerance through mechanisms related to central sensitization, it does not do so by MOR displacement.
Option E: Option E is incorrect because ketamine is not a partial MOR agonist; its primary mechanism of action is NMDA receptor open-channel blockade, with MOR activity being negligible at analgesic doses.
10. A patient with Child-Pugh Class C hepatic cirrhosis is maintained on methadone 80 mg/day for opioid use disorder (OUD). His liver function has worsened over the past two months. Applying the pharmacokinetic consequences of severe hepatic impairment to methadone specifically, which of the following best predicts the net pharmacokinetic effect and the resulting clinical risk?
A) Severe hepatic impairment accelerates methadone clearance by shunting metabolism from the saturated CYP3A4 pathway to CYP2D6 and CYP2B6 isoforms, which are upregulated in cirrhosis; the net effect is a shorter methadone half-life requiring dose increases to maintain adequate plasma concentrations for OUD suppression
B) Severe hepatic impairment has no clinically meaningful effect on methadone pharmacokinetics because methadone's primary elimination is through fecal excretion of unchanged parent compound, bypassing hepatic metabolism entirely; plasma concentrations remain stable without dose adjustment in Child-Pugh Class C
C) Severe hepatic impairment increases renal tubular secretion of methadone through a compensatory hepatorenal reflex, maintaining near-normal total body clearance despite reduced hepatic metabolism; the net plasma methadone concentration changes minimally, but the proportion of renally excreted parent compound increases, raising the risk of nephrotoxicity
D) Severe hepatic impairment reduces CYP3A4-mediated methadone metabolism, prolonging its half-life and increasing plasma concentrations; reduced albumin and alpha-1-acid glycoprotein synthesis increases the free methadone fraction; and reduced first-pass extraction increases oral bioavailability — the net effect is substantially elevated plasma methadone exposure with a higher free drug fraction, increasing the risk of opioid toxicity and QTc prolongation at the previously tolerated dose
E) Severe hepatic impairment reduces methadone's volume of distribution by impairing hepatic uptake into the liver tissue compartment, paradoxically raising plasma methadone concentrations while reducing tissue concentrations; the clinical consequence is increased plasma toxicity but reduced tissue-level opioid effect, producing a dissociation between plasma concentration monitoring and analgesic or OUD suppression efficacy
ANSWER: D
Rationale:
This question asked you to integrate multiple pharmacokinetic consequences of severe hepatic impairment as they apply specifically to methadone. Option D is correct. Methadone undergoes several hepatic processes that are all impaired in Child-Pugh Class C cirrhosis, and each impairment contributes to elevated plasma drug exposure. First, CYP3A4-mediated metabolism is the primary route of methadone elimination; reduced CYP3A4 activity in severe cirrhosis prolongs methadone's already long and variable half-life (typically 24–36 hours in normal hepatic function) further, slowing clearance and raising steady-state plasma concentrations. Second, reduced hepatic synthesis of albumin and alpha-1-acid glycoprotein — the primary plasma proteins binding methadone — increases the unbound (free) drug fraction; since it is the free drug that produces pharmacological effects and adverse effects, this increases the active methadone concentration above what total plasma concentration measurements indicate. Third, reduced first-pass hepatic extraction increases the oral bioavailability of methadone, meaning that the same oral dose delivers more drug to the systemic circulation. The combination of these three mechanisms produces substantially elevated total and free methadone plasma exposure at the previously tolerated dose, increasing the risk of MOR-mediated opioid toxicity (sedation, respiratory depression) and QTc prolongation through hERG channel blockade (which is concentration-dependent).
Option A: Option A is incorrect because hepatic impairment does not upregulate CYP2D6 or CYP2B6 to compensate; all CYP isoforms are generally reduced in severe cirrhosis, and a shorter half-life requiring dose increases is the opposite of what occurs.
Option B: Option B is incorrect because while methadone does have fecal excretion as an important elimination route, CYP3A4-mediated hepatic metabolism is also a major clearance pathway; stating that fecal excretion bypasses hepatic metabolism entirely misrepresents methadone's pharmacokinetics, and Child-Pugh Class C does significantly alter methadone disposition.
Option C: Option C is incorrect because compensatory renal tubular secretion through a hepatorenal reflex is not an established pharmacokinetic mechanism for methadone or any other opioid, and methadone is not nephrotoxic.
Option E: Option E is incorrect because hepatic impairment does not reduce methadone's volume of distribution by impairing hepatic tissue uptake in the manner described; methadone's high volume of distribution reflects extensive tissue distribution throughout the body, and cirrhosis alters its hepatic metabolism and protein binding rather than producing the tissue-versus-plasma dissociation described.
11. An opioid-naive patient with advanced lung cancer reports severe dyspnea at rest. Her palliative care team initiates morphine 2.5 mg orally every 4 hours for breathlessness relief rather than the 10–15 mg doses they would use for her pain. Which of the following best explains why a lower morphine dose achieves dyspnea relief in opioid-naive patients and how this relates to the underlying mechanism of action?
A) Lower morphine doses are used for dyspnea because respiratory depression begins at doses below those required for analgesia; morphine relieves dyspnea by producing mild respiratory depression — reducing respiratory rate and tidal volume — and the dyspnea dose is titrated to the minimum respiratory depression needed to slow breathing to a comfortable rate without causing apnea
B) Lower morphine doses are used for dyspnea because opioid-naive patients have higher MOR sensitivity than opioid-tolerant patients; the same dose produces more mu-opioid receptor (MOR) activation in opioid-naive patients, and the dyspnea dose is calibrated to the sensitivity differential rather than to a pharmacodynamically distinct dyspnea-relief mechanism
C) The brainstem circuits mediating the subjective perception of breathlessness — air hunger — and the drive to breathe are sensitive to MOR agonism at concentrations below those required to activate the supraspinal and spinal MOR circuits that modulate pain; morphine relieves dyspnea by reducing the central respiratory drive and the affective perception of air hunger through brainstem MOR activation at doses lower than those needed for analgesic efficacy, and relief of the subjective sensation occurs even when objective respiratory parameters such as rate and oxygen saturation remain unchanged
D) Lower morphine doses are used for dyspnea because the lung contains a high density of peripheral MOR on pulmonary stretch receptors; morphine relieves dyspnea primarily through peripheral MOR activation at these stretch receptors, which requires lower plasma concentrations than are needed to cross the blood-brain barrier in sufficient quantities to produce central analgesia
E) The dose difference reflects route-of-administration pharmacokinetics rather than a mechanistic difference; when morphine is given orally for dyspnea versus intravenously for pain, the lower oral bioavailability (approximately 30%) means that 2.5 mg oral morphine produces equivalent central MOR activation to 10 mg IV morphine, and the dyspnea and analgesic mechanisms are therefore pharmacodynamically identical at equivalent plasma concentrations
ANSWER: C
Rationale:
This question asked you to explain the mechanistic basis for the lower morphine dose required for dyspnea relief compared to analgesia. Option C is correct. Morphine relieves dyspnea through MOR activation in brainstem respiratory control centers — including circuits that regulate respiratory drive and the affective perception of breathlessness (air hunger). The key clinical observation is that dyspnea relief in opioid-naive patients is achieved at doses substantially lower than standard analgesic doses (morphine 2.5–5 mg orally every 4 hours versus 10–15 mg for pain), and that this relief occurs even when objective respiratory parameters — rate, tidal volume, and oxygen saturation — do not normalize. This suggests that the threshold for MOR-mediated modulation of the subjective air hunger perception in brainstem circuits is lower than the threshold for activating the full spectrum of supraspinal and spinal MOR circuits required for meaningful pain modulation. The mechanism is central — brainstem MOR activation reducing both the physiological drive to breathe and the subjective perception of respiratory effort — not peripheral. In opioid-tolerant patients requiring opioids for pain management, additional opioid above the analgesic baseline may be required to achieve dyspnea relief, consistent with the concept that tolerance affects the dyspnea-relief pathway proportionally.
Option A: Option A is incorrect because the goal of morphine for dyspnea is not to produce respiratory depression as the therapeutic mechanism; the relief of subjective breathlessness occurs through central perception modulation, and measuring success by objective respiratory parameter changes (rate, tidal volume) misidentifies the therapeutic endpoint. Titrating to the minimum respiratory depression needed to slow breathing would be clinically dangerous.
Option B: Option B is incorrect because while opioid-naive patients do have higher MOR sensitivity than opioid-tolerant patients, the dose difference between dyspnea relief and analgesia exists within opioid-naive patients and is not explained by the naive-versus-tolerant distinction; it reflects a pharmacodynamic difference in the MOR activation thresholds of dyspnea versus pain circuits.
Option D: Option D is incorrect because morphine does not primarily relieve dyspnea through peripheral MOR at pulmonary stretch receptors; the mechanism is central brainstem MOR activation, and peripheral pulmonary MOR density is not established as the explanation for the lower dyspnea dose.
Option E: Option E is incorrect because the dose difference is not a route-of-administration artifact; opioid-naive patients receiving the same equianalgesic plasma concentrations for dyspnea as for pain would receive far more opioid than required for breathlessness relief, demonstrating that the mechanisms are pharmacodynamically distinct rather than equivalent at matched plasma concentrations.
12. Emergency responders administer standard-dose naloxone 0.4 mg intramuscularly to a 28-year-old man found unresponsive after presumed illicit opioid use in a community where illicitly manufactured fentanyl (IMF) is prevalent. He regains consciousness briefly but becomes unresponsive again within 20 minutes. Applying knowledge of fentanyl's pharmacokinetics and IMF's potency, which of the following best explains this clinical course and identifies the correct management principle?
A) Fentanyl's high lipophilicity produces rapid initial CNS penetration causing the overdose, but drug redistributes from the CNS back into peripheral tissues over 20–30 minutes; naloxone's shorter duration of action (45–90 minutes at standard doses) relative to fentanyl's effective CNS concentration-time profile, combined with fentanyl's potential for redistribution-driven resedation as peripheral tissue concentrations re-equilibrate, explains the recurrent unresponsiveness; management requires repeat naloxone dosing, higher naloxone doses, or naloxone infusion, with continuous monitoring for resedation
B) The recurrent unresponsiveness reflects naloxone's mu-opioid receptor (MOR) agonist activity at high CNS concentrations after intramuscular injection; once naloxone reaches peak CNS concentrations, it activates MOR at supraspinal sites and produces sedation indistinguishable from opioid overdose; the correct management is to withhold further naloxone and support ventilation until naloxone redistributes out of the CNS
C) IMF produces irreversible covalent binding to MOR that cannot be overcome by standard naloxone doses; the initial response to naloxone reflects displacement of non-covalently bound fentanyl from a superficial receptor pool, while the recurrent unresponsiveness reflects the irreversibly bound fentanyl fraction reasserting its effect as the displaced fentanyl pool recovers; management requires high-dose naloxone administered as a continuous infusion for 24 hours
D) The recurrent unresponsiveness reflects fentanyl-induced downregulation of MOR during the initial overdose period; when naloxone competitively occupies MOR, it accelerates receptor internalization and reduces total MOR density, leaving fewer receptors for endogenous opioids to activate and producing a functional opioid-deficient state that mimics overdose; management is supportive care without further naloxone
E) IMF's extreme potency means that the total drug dose in a typical exposure far exceeds what standard naloxone doses can reverse; the recurrent unresponsiveness occurs because naloxone reverses only the fraction of MOR occupied by the amount of fentanyl equianalgesic to 0.4 mg naloxone's competitive displacement capacity, while the remaining fentanyl-bound MOR fraction continues to produce respiratory depression; management requires calculating the exact fentanyl dose and administering precisely equimolar naloxone
ANSWER: A
Rationale:
This question asked you to integrate fentanyl's pharmacokinetic properties with naloxone's duration of action to explain resedation after initial opioid reversal in an IMF overdose. Option A is correct. Fentanyl's high lipophilicity drives its rapid initial CNS penetration after administration — the same property that makes it fast-acting clinically also means it equilibrates quickly between plasma, CNS, and peripheral tissue compartments. After an acute overdose, as plasma fentanyl concentrations fall (through redistribution into peripheral fat and muscle), drug moves back from peripheral compartments into plasma and can re-enter the CNS — a redistribution resedation phenomenon. Critically, naloxone has a shorter effective duration of action (approximately 45–90 minutes at standard doses) than the duration over which fentanyl can sustain clinically significant CNS concentrations in an overdose involving the quantities typically present in IMF exposures. When naloxone's competitive MOR blockade wanes before fentanyl has been fully eliminated or redistributed away from the CNS, resedation occurs. This is particularly relevant with IMF because the extreme potency of illicitly manufactured fentanyl means that even small absolute amounts produce profound and prolonged MOR activation. Management requires repeat naloxone doses, higher naloxone doses titrated to respiratory response, or a continuous naloxone infusion, combined with continuous monitoring in a medical setting because resedation can be fatal if the patient is discharged prematurely after initial response.
Option B: Option B is incorrect because naloxone is a competitive MOR antagonist with no intrinsic MOR agonist activity at any dose; it does not activate MOR or produce sedation.
Option C: Option C is incorrect because fentanyl does not form irreversible covalent bonds with MOR; it is a competitive, reversible MOR agonist. Naloxone can fully displace fentanyl from MOR at adequate doses, and the concept of irreversibly bound fentanyl requiring 24-hour infusion is pharmacologically false.
Option D: Option D is incorrect because fentanyl-induced MOR downregulation during an acute overdose is not an established mechanism producing recurrent unresponsiveness after naloxone; acute receptor internalization during a brief overdose period does not cause the pattern described, and naloxone does not accelerate receptor internalization in a clinically harmful way.
Option E: Option E is incorrect because naloxone reversal does not require equimolar stoichiometry to fentanyl; naloxone's competitive displacement works through pharmacodynamic receptor competition, not molecular equivalence, and calculating "equimolar naloxone" is not a clinical or pharmacological concept applicable to opioid reversal.
13. A patient with chronic low back pain on long-term oxycodone 40 mg twice daily reports that his pain has worsened progressively over the past three months despite dose increases, and that he is now experiencing diffuse pain extending beyond his original back pain distribution. His clinician suspects opioid-induced hyperalgesia (OIH) rather than opioid tolerance. Which of the following correctly distinguishes OIH from tolerance mechanistically and identifies the correct clinical implication of this distinction?
A) OIH and opioid tolerance are mechanistically identical — both result from mu-opioid receptor (MOR) downregulation and uncoupling from Gi/Go proteins through beta-arrestin-mediated internalization; the clinical distinction is purely quantitative, with tolerance representing mild-to-moderate receptor downregulation and OIH representing severe receptor downregulation that produces pain sensitization through disinhibition of ascending nociceptive pathways
B) Opioid tolerance is a pharmacodynamic adaptation in which chronic MOR activation reduces the analgesic effect of a given dose through receptor downregulation and signal desensitization — requiring dose escalation to maintain equivalent analgesia; OIH is a paradoxical state in which chronic opioid exposure activates N-methyl-D-aspartate (NMDA) receptor-mediated central sensitization and pronociceptive pathways, producing a diffuse increase in pain sensitivity that worsens with dose escalation; the critical clinical distinction is that tolerance is treated by dose increase while OIH is worsened by it — requiring opioid dose reduction or rotation, and potentially NMDA antagonist therapy
C) Tolerance develops rapidly (within days) and is fully reversible upon opioid cessation within 24 hours; OIH develops only after years of continuous opioid exposure and is irreversible once established, persisting indefinitely after opioid discontinuation due to permanent NMDA receptor structural changes; the clinical implication is that OIH requires permanent opioid cessation with no possibility of future opioid prescribing
D) The distinction between OIH and tolerance is clinically irrelevant because both conditions respond to the same intervention — switching to methadone, whose NMDA antagonist activity simultaneously addresses the NMDA-mediated component of OIH and restores analgesic efficacy lost through tolerance; methadone rotation is therefore the universal correct response to any case of worsening pain on chronic opioid therapy
E) OIH is caused by accumulation of pro-nociceptive opioid metabolites (specifically morphine-3-glucuronide in the case of oxycodone) that activate neuroexcitatory receptors; distinguishing OIH from tolerance requires measuring plasma metabolite concentrations, and OIH is treated by switching to an opioid with fewer pro-nociceptive metabolites rather than by dose reduction
ANSWER: B
Rationale:
This question asked you to distinguish the mechanisms of OIH and opioid tolerance and identify the critical clinical implication of that distinction. Option B is correct. Opioid tolerance is a pharmacodynamic adaptation in which chronic MOR activation leads to receptor desensitization (uncoupling from Gi/Go proteins), downregulation (reduced surface MOR expression through internalization), and compensatory upregulation of adenylyl cyclase activity — collectively producing a reduced analgesic response to a given dose, requiring escalation to maintain the same effect. OIH is a mechanistically distinct and clinically opposite phenomenon: chronic opioid exposure activates NMDA receptor-mediated pronociceptive processes in the dorsal horn, enhancing central sensitization and upregulating pain transmission pathways including dynorphin-mediated spinal sensitization, descending facilitation from the rostral ventromedial medulla (RVM), and glutamate-driven synaptic amplification. The result is a paradoxical increase in pain sensitivity — diffuse, extending beyond the original pain distribution, and worsening with dose escalation rather than improving. The clinical implication is the critical point: a clinician who misidentifies OIH as tolerance will escalate the dose, worsening the central sensitization and the patient's pain. The correct response to suspected OIH is opioid dose reduction or rotation (to a different opioid, as cross-sensitization is incomplete), and NMDA receptor antagonists (ketamine, methadone at its NMDA-blocking mechanism) may address the underlying sensitization mechanism.
Option A: Option A is incorrect because OIH and tolerance are mechanistically distinct — tolerance is MOR desensitization and downregulation, while OIH involves NMDA receptor activation and pronociceptive pathway upregulation; describing them as mechanistically identical with only quantitative differences is pharmacologically incorrect and would lead to the same dangerous clinical error of dose escalation in OIH.
Option C: Option C is incorrect because both tolerance and OIH develop over a variable time course — neither has the fixed timelines stated — and OIH is not established as irreversible due to permanent structural NMDA receptor changes; pain sensitization in OIH generally improves with opioid reduction or cessation, though the time course varies.
Option D: Option D is incorrect because methadone rotation is not the universal response to all worsening pain on chronic opioids; while methadone's NMDA antagonism is a legitimate consideration in OIH, the statement that the distinction between OIH and tolerance is clinically irrelevant is wrong — precisely because the treatment of tolerance (dose increase) is contraindicated in OIH.
Option E: Option E is incorrect because OIH from oxycodone is not caused by M3G accumulation; M3G is a morphine metabolite, not an oxycodone metabolite. OIH from oxycodone involves central sensitization mechanisms, not metabolite-specific neuroexcitatory effects, and plasma metabolite measurement is not the clinical tool for distinguishing OIH from tolerance.
QUESTION ANSWER KEY
Q1: D | Q2: A | Q3: E | Q4: B | Q5: C | Q6: D | Q7: A | Q8: E | Q9: B | Q10: D | Q11: C | Q12: A | Q13: B
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.